anti-CD19 UCAR-NK cells

Anti-CD19 UCAR-NK cells are a type of chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19, a surface antigen expressed on B cells. The "UCAR" likely refers to "Universal CAR," indicating these are allogeneic (off-the-shelf) NK cells engineered to express a CD19-targeting receptor. This therapy combines the specificity of CAR technology with the natural cytotoxic abilities of NK cells, offering potential advantages over CAR-T cell therapy including reduced risk of cytokine release syndrome (CRS), graft-versus-host disease (GvHD), and neurotoxicity. Clinical trials with CD19 CAR-NK cells have shown promising results in patients with B-cell malignancies, with complete remission rates of up to 73% in some studies.